Elevar Therapeutics, a late-stage biopharmaceutical company focused on promising therapies for unmet medical needs in cancer, announced today the initiation of a pivotal trial for the treatment of adenoid cystic cancer (ACC) with the enrollment of the first patient at the University of California, San Francisco Division of Hematology and Oncology.

Full Text: https://elevartherapeutics.com/2020/03/09/elevar-therapeutics-announces-enrollment-of-the-first-patient-in-a-pivotal-trial-for-the-treatment-of-adenoid-cystic-cancer-acc/